Scanning electron micrograph of an apoptotic HeLa cancer cell. Thomas Deerinck, UC San Diego
Cancer Researchers Receive $4 Million CIRM Disease-Team Grant
Researcher Thomas J. Kipps, MD, PhD, professor of medicine and deputy director of research operations at UC San Diego Moores Cancer Center, is principal investigator for one of six “Disease Team” awards approved December 12 by the governing board of the California Institute for Regenerative Medicine (CIRM).  The grant, for $4.18 million, is part of a total $61 million awarded to fund work which promises to move therapies out of the lab and into clinical trials in patients.
The funding was approved by the stem cell agency’s governing board, the Independent Citizen’s Oversight Committee (ICOC), at a two-day meeting in Los Angeles.
The UC San Diego research team’s goal is to develop new therapies that specifically target a protein found only on the surface of cancer stem cells. The protein, called Receptor-tyrosine-kinase-like Orphan Receptor 1 or ROR1, is produced in great amounts during embryogenesis, when it helps regulate early muscle and skeletal development. Later, ROR1 is turned off.  Normal cells and tissues in adults do not typically express ROR1.
But multiple types of cancer stem cells do, co-opting ROR1 to promote their growth and survival. In fact, Kipps and colleagues have found that exploitation of ROR1 by cancer cells is critical to the disease’s spread or metastasis, estimated to be responsible for 90 percent of cancer-related deaths.
With earlier CIRM funding, Kipps, fellow researcher Catriona Jamieson, MD, PhD – associate professor of medicine and director of the stem cell research program at Moores Cancer Center – and colleagues developed a humanized monoclonal antibody that specifically targets and inhibits the functioning of ROR1.
“Because this antibody does not bind to normal cells, it can serve as the ‘magic bullet’ to deliver a specific hit to cancer stem cells,” the researchers said in their CIRM proposal.
They plan to conduct clinical trials with the antibody, first in patients with chronic lymphocytic leukemia, the most common type of blood cancer in the United States, to determine appropriate dose levels and safety protocols, followed by clinical trials involving patients with other types of cancer, including solid tumor types like breast and lung.
“We will investigate the potential for using this antibody to deliver toxins selectively to cancer stem cells,” the researchers wrote. “This selective delivery could be very active in killing cancer stem cells without harming normal cells in the body because they lack expression of ROR1. With this antibody, we can develop curative stem-cell-directed therapy for patients with any one of many different types of currently intractable cancers.”
The CIRM Disease Team awards are designed to encourage multidisciplinary teams of researchers from academic institutions, medical centers and industry to work together and to develop new treatments for a broad range of therapies. The recipients were selected from 14 applications, all of which were reviewed by an independent group of internationally renowned scientists.

Scanning electron micrograph of an apoptotic HeLa cancer cell. Thomas Deerinck, UC San Diego

Cancer Researchers Receive $4 Million CIRM Disease-Team Grant

Researcher Thomas J. Kipps, MD, PhD, professor of medicine and deputy director of research operations at UC San Diego Moores Cancer Center, is principal investigator for one of six “Disease Team” awards approved December 12 by the governing board of the California Institute for Regenerative Medicine (CIRM).  The grant, for $4.18 million, is part of a total $61 million awarded to fund work which promises to move therapies out of the lab and into clinical trials in patients.

The funding was approved by the stem cell agency’s governing board, the Independent Citizen’s Oversight Committee (ICOC), at a two-day meeting in Los Angeles.

The UC San Diego research team’s goal is to develop new therapies that specifically target a protein found only on the surface of cancer stem cells. The protein, called Receptor-tyrosine-kinase-like Orphan Receptor 1 or ROR1, is produced in great amounts during embryogenesis, when it helps regulate early muscle and skeletal development. Later, ROR1 is turned off.  Normal cells and tissues in adults do not typically express ROR1.

But multiple types of cancer stem cells do, co-opting ROR1 to promote their growth and survival. In fact, Kipps and colleagues have found that exploitation of ROR1 by cancer cells is critical to the disease’s spread or metastasis, estimated to be responsible for 90 percent of cancer-related deaths.

With earlier CIRM funding, Kipps, fellow researcher Catriona Jamieson, MD, PhD – associate professor of medicine and director of the stem cell research program at Moores Cancer Center – and colleagues developed a humanized monoclonal antibody that specifically targets and inhibits the functioning of ROR1.

“Because this antibody does not bind to normal cells, it can serve as the ‘magic bullet’ to deliver a specific hit to cancer stem cells,” the researchers said in their CIRM proposal.

They plan to conduct clinical trials with the antibody, first in patients with chronic lymphocytic leukemia, the most common type of blood cancer in the United States, to determine appropriate dose levels and safety protocols, followed by clinical trials involving patients with other types of cancer, including solid tumor types like breast and lung.

“We will investigate the potential for using this antibody to deliver toxins selectively to cancer stem cells,” the researchers wrote. “This selective delivery could be very active in killing cancer stem cells without harming normal cells in the body because they lack expression of ROR1. With this antibody, we can develop curative stem-cell-directed therapy for patients with any one of many different types of currently intractable cancers.”

The CIRM Disease Team awards are designed to encourage multidisciplinary teams of researchers from academic institutions, medical centers and industry to work together and to develop new treatments for a broad range of therapies. The recipients were selected from 14 applications, all of which were reviewed by an independent group of internationally renowned scientists.

Notes

  1. muddycarr reblogged this from biologylair
  2. satoshi413 reblogged this from ucsdhealthsciences and added:
    @lisestephanie
  3. aberrantbiology reblogged this from biologylair
  4. madrid-kid reblogged this from whats-krakenn
  5. whats-krakenn reblogged this from biologylair
  6. mp-xiii reblogged this from biologylair
  7. recortable reblogged this from biologylair
  8. diamidinophenylindolee reblogged this from biologylair
  9. kaleiopus reblogged this from biologylair
  10. sabrina---bee reblogged this from biologylair
  11. howlyhowls reblogged this from ucsdhealthsciences
  12. polysymphony reblogged this from biologylair
  13. extraterrestrial-dragon reblogged this from biologylair
  14. ravenwhimsy reblogged this from fat-old-sunn
  15. dharmae reblogged this from ucsdhealthsciences
  16. drmohamedkhalid reblogged this from ucsdhealthsciences
  17. aufdererbse reblogged this from pornoes
  18. it-evermore reblogged this from ucsdhealthsciences
  19. yes-siree-dodd reblogged this from quantum-immortal
  20. quantum-immortal reblogged this from ucsdhealthsciences
  21. dovahkiiiin reblogged this from giacere
  22. 1010wins reblogged this from sgust
  23. jpeg2001 reblogged this from pornoes
  24. forestfaerie reblogged this from pornoes
  25. giacere reblogged this from sgust

About

News from UC San Diego Health Sciences
Media Contacts: 619-543-6163
HealthSciComm@ucsd.edu

Blogroll

  • afro-dominicano
  • americanpublicmedia
  • sdzoo
  • comedycentral
  • mindblowingscience
  • libertasacademica
  • latimes
  • ucsdzone
  • salon
  • msnbc
  • medresearch
  • publicradiointernational
  • journalofajournalist
  • azspot
  • wnyc
  • scienceyoucanlove
  • scishow
  • wired
  • melon-collies
  • theonion
  • neurosciencestuff
  • forum-network
  • theweekmagazine
  • washingtonpost
  • photojojo
  • pozmagazine
  • nydailynews
  • newsweek
  • fastcompany
  • todaysdocument
  • amnhnyc
  • scientificillustration
  • mothernaturenetwork
  • longform
  • kqedscience
  • wnycradiolab
  • explore-blog
  • nbcnightlynews
  • katiecouric
  • guardian
  • abcworldnews
  • think-progress
  • pritheworld
  • huffingtonpost
  • tballardbrown
  • ucrhub
  • thisisfusion
  • rollingstone
  • sciencefriday
  • therumpus
  • staff
  • breakingnews
  • science-junkie
  • oupacademic
  • ucsdspecialcollections
  • npr
  • plannedparenthood
  • mashablehq
  • nysci
  • dodgemedlin
  • scipak
  • nprfreshair
  • pbstv
  • sdzsafaripark
  • cranquis
  • newyorker
  • boston
  • prnewswire
  • usagov
  • pulitzercenter
  • buzzfeed
  • prochoiceamerica
  • skunkbear
  • princeton-medbloro
  • jtotheizzoe
  • cenwatchglass
  • washingtonexaminer
  • infographicjournal
  • unicef
  • instagram
  • soupsoup
  • 3rdofmay
  • nursefocker
  • medicalschool
  • thebrainscoop
  • wsudiscovery
  • ucresearch
  • newswatchtv
  • md-admissions
  • ucsdcrossculturalcenter
  • houseofmind
  • lakeconews
  • usatoday
  • onaissues
  • pubhealth
  • wayfaringmd
  • doublejack
  • sciencenetlinks
  • forbes
  • thedailyshow
  • medindia
  • stemcellculture
  • inothernews
  • brookhavenlab
  • currentsinbiology
  • cnbc
  • actgnetwork
  • timelightbox
  • madsweat
  • pbsthisdayinhistory
  • ziyadnazem
  • post-mitotic
  • aspiringdoctors
  • scienceisbeauty
  • smithsonianmag
  • mediclopedia
  • seltzerlizard
  • lewisandquark
  • whitehouse
  • bbglasses
  • science-and-logic
  • psychotherapy
  • thescienceblog
  • thevancouversun
  • mathcat345
  • statedept
  • usnews
  • medicalstate
  • lookatthisstory
  • shortformblog
  • austinstatesman
  • csmonitor
  • sesamestreet
  • doctorswithoutborders
  • queerability
  • yahoonews
  • scienceandfood
  • columbusdispatch
  • newshour
  • scinerds
  • uconnhealthlib
  • hospitalreina
  • biocanvas
  • ucsciencetoday
  • articulomortis
  • nprglobalhealth
  • codeit
  • cancerninja
  • robertreich
  • laboratoryequipment
  • peacecorps
  • researchchla
  • minnpost
  • today
  • scientificthought
  • yaleuniversity
  • missmdisme
  • exploratorium
  • nprontheroad
  • sciencesoup
  • alscientist
  • healthcareinfoguide
  • ari-abroad
  • theskygazer
  • highcountrynews
  • natgeofound
  • timemagazine
  • artandsciencejournal
  • aarp
  • officialssay
  • nbcnews
  • thisissandiego
  • nypl
  • psydoctor8
  • artneuroscience
  • bbsrc
  • anaofta
  • tmagazine
  • shortyawards
  • molecularlifesciences
  • blamoscience
  • markcoatney
  • reuters
  • jayparkinsonmd
  • ottawahealth
  • fyeahmedlab
  • blue-lights-and-tea
  • fuckyeahneuroscience
  • htdeverything
  • mediamed
  • phdr
  • topherchris
  • kateoplis
  • ohscience
  • artpoweratucsd
  • ucsdcancer
  • denverpost
  • motherjones
  • discoverynews
  • michiganengineering
  • oh4theloveofscience
  • nurse-on-duty
  • thenewrepublic
  • wgbhnews
  • theatlantic
  • colchrishadfield
  • fuckyeahcardiovascularsystem
  • fuckyeahnervoussystem
  • sciencenote
  • matthewkeys
  • robotmuesli
  • pneupnurse
  • medethicslady
  • themedicalchronicles
  • kpcc
  • ohyeahdevelopmentalbiology
  • ucsdcareerservicescenter
  • science
  • pacificstand
  • clearscience
  • bitesizedbiology
  • poptech
  • futureofscience
  • galindoyadira
  • genannetics
  • ucsd
  • ucsdmedialab
  • joshherigon
  • thescienceofreality
  • ladyjournos
  • sciencechicks
  • auditoryinsomniac
  • chronicleofhighered
  • vetstail
  • neurolove
  • ajebsary
  • neuroanatomyblog
  • goodideapublichealth
  • tedx
  • huffpostscience
  • thecoloradopursuit
  • brainmtters
  • bobedwardsradio
  • paraphyletic
  • sci-fact
  • nationalpost
  • carlzimmer
  • life
  • dailymedical
  • oceanportal
  • bklynmed
  • wellcomebrains
  • aljazeera
  • reportingonhealth
  • ucsfbioengineering
  • coolhealthinfographics
  • thedailywhat
  • villagevoice
  • nbclatino
  • guardiancomment
  • scientificbritain
  • adschu